The L1 Adhesion Molecule Is a Cellular Ligand for VLA-5

Michael Ruppert,* Silke Aigner,* Marcus Hubbe,* Hideo Yagita,† and Peter Altevogt*

*Tumor Immunology Programme, 0710, German Cancer Research Center, D-69120 Heidelberg, Germany, and†Department of Immunology, Juntendo University School of Medicine, Tokyo 113, Japan

Abstract. The L1 adhesion molecule is a member of the immunoglobulin superfamily shared by neural and immune cells. In the nervous system L1 can mediate cell binding by a homophilic mechanism. To analyze its function on leukocytes we studied whether L1 could interact with integrins. Here we demonstrate that VLA-5, an RGD-specific fibronectin receptor on a wide variety of cell types, can bind to murine L1. Mouse ESb-MP cells expressing VLA-5 and L1 could be induced to aggregate in the presence of specific mAbs to CD24 (heat-stable antigen), a highly and heterogeneously glycosylated glycosylphosphatidylinositol-linked differentiation antigen of hematopoietic and neural cells. The aggregation was blocked by both mAbs to L1 and VLA-5, respectively. Aggregation was blocked also by a synthetic RGD-containing peptide derived from the Ig-domain VI of the L1 protein. ESb-MP subclones with low L1 expression could not aggregate. In heterotypic binding assays mouse bone marrow cells could adhere in an L1-dependent fashion to platelets that expressed VLA-5. Also purified L1 coated to polystyrene beads could bind to platelets. The binding of L1-beads was again inhibited by mAbs to L1 and VLA-5, by soluble L1 and the L1-RGD peptide in a dose-dependent manner. Thymocytes or human Nalm-6 tumor cells expressing VLA-5 could adhere to affinity-purified L1 and to the L1-derived RGD-containing peptide coated to glass slides. The adhesion was strongly enhanced in the presence of Mn²⁺-ions and blocked by mAbs to VLA-5. We also demonstrate a direct L1–VLA-5 protein interaction. Our results suggest a novel binding pathway, in which the VLA-5 integrin binds to L1 on adjacent cells. Given its rapid downregulation on lymphocytes after induction of cell proliferation, L1 may be important in integrin-mediated and activation-regulated cell–cell interactions.

Leukocyte function is crucially dependent on cell-adhesion which provides the necessary mechanical stability for cell–cell contact but may also deliver signals from the micro-environment. Integrins have been shown to be important activation-dependent adhesion molecules that possess also signaling potential (for review see reference 37). On leukocytes, integrins are involved in cell–cell and cell–extracellular matrix interactions and play a role in physiological processes such as the regulation of lymphocyte responses to antigenic stimulation, the recirculation into lymphoid tissues or the extravasation at sites of inflammation (for reviews see reference 17, 78). The β2-integrins LFA-1 (αLβ2) and Mac-1 (αMβ2) and the α4-integrins participate in distinct mechanisms for leukocyte–endothelial and leukocyte–leukocyte binding (for review see reference 20). Several members of the Ig superfamily have been identified as cell surface ligands for these integrins. LFA-1, can bind to intercellular cell adhesion molecule (ICAM)-1 or ICAM-2 on the surface of stimulated or unstimulated endothelial cells or to ICAM-3 on lymphocytes. ICAM-1 and ICAM-2 are not restricted to endothelial cells but are also expressed by leukocytes and are involved in many leukocyte functions including the recognition of target cells by cytotoxic T lymphocytes and the collaboration of T- and B-lymphocytes. The α4-integrins VLA-4 (α4β1) and LPAM-1 (α4β7) mediate leukocyte adhesion to the vascular cell adhesion molecule VCAM-1 (65), and the addressin MadCAM-1 (9). These interactions are important for the migration and recirculation of lymphocytes from the blood stream into lymphoid organs. VLA-4 can also support the binding of leukocytes to fibronectin involving an LDV peptide motif in the HepII/IIICS region of fibronectin (CS-1 peptide) (30, 48).

Other integrins of the VLA family promote the binding of leukocytes to extracellular matrix components like laminin, collagen or fibronectin (for review see 34, 36). The VLA-5 integrin is the classical fibronectin receptor and it binds to fibronectin via an RGD-sequence in the

1. Abbreviations used in this paper: 2-ME, 2-mercaptoethanol; BOG, β-octylglucoside; GPI, glycosylphosphatidylinositol; ICAM, intercellular adhesion molecule; PE, phycoerythrin.
Materials and Methods

Cell Culture

The murine bend3 endothelioma cell line was kindly provided by Dr. W. Risau (Max-Planck Institut Bad Nauheim, Germany) and was maintained in DME with high Glucose (Life Technologies, Eggenstein, Germany), containing 10% FBS (low endotoxin; Life Technologies). All cells were kept at 37°C, 5% CO2, and 100% humidity. Thymocytes in DME with high Glucose (Life Technologies, Eggenstein, Germany) were used as antigen-presenting cells for hybridoma cell lines. The monocytic tumor cell line ESb-MP was cultivated in RPMI 1640 supplemented with 10% FBS, 2-mercaptoethanol (2-ME), Hepes, and Glutamine as previously described (10). Bone marrow, mature thymocytes and the majority of peripheral B and T lymphocytes express the antigen. Whereas the function of L1 in the nervous system is well established its role in the adhesion of leukocytes is not known.

Here we report that the L1 adhesion molecule as well as an RGD-containing peptide derived from the L1 sequence can serve as a ligand for VLA-5. In the presence of mAbs to CD24, a highly glycosylated glycoprophatidyl inositol-linked differentiation antigen, mouse ESb-MP cells could aggregate in an L1 and VLA-5-dependent manner. Our results suggest that VLA-5 and L1 constitute a novel binding pathway involved in homotypic and heterotypic cell adhesion. Given its rapid downregulation on lymphocytes and neutrophils after cell activation (35), L1 may be important in integrin-mediated and activation-regulated interactions of leukocytes during the immune response. The VLA-5-L1 binding pathway may also be important in other cell-cell interactions.

Affinity Purification of Cell Surface Antigens

L1 was purified by affinity chromatography on a mAb 324 column from lysates of ESb-MP cells or N2A neuroblastoma cells essentially as described elsewhere (35). CD2 was isolated from mouse thymocyte lysate on a mAb 12-15-Sepharose column. The elution buffer contained 100 mM diethylamine/HC1, pH 11.5, 150 mM NaCl with 50 mM 13-octylglucoside (BOG). Soluble L1 from mouse brain was a gift from Dr. G. Kadmon (DKFZ, Heidelberg, Germany). VLA-5 was isolated from thymocyte lysate on a HMos-1-Sepharose column. The antigen was eluted with 0.2 M acetic acid, 50 mM BOG, 500 mM NaCl containing 2 mM CaCl2 and MgCl2. Eluted fractions were neutralized and analyzed by ELISA with rF1 antibody to mouse a5b1 integrin, (Becton Dickinson, Heidelberg, Germany). HMa5-1 and HMa5-2 (mAb c5(2)) are blocking antibodies to mouse a5 integrin (88). mAb RMV-7 is a blocking antibody to mouse vitronectin receptor on lymphocytes (79). mAb RB40.34 recognizing mouse P-selectin (12) was a gift of D. Vestweber (Max-Planck Institute für Immunobiologie, Freiburg, Germany). mAb EA-1 (39) against mouse a6 integrin was a gift of B. Imhof (BASF Institute for Immunology, Basel, Switzerland). The mAb to human VLA-5 (Sam-1) was obtained from Dianova. The anti-human CD24 mAb MLS was obtained from Dr. S. Funderud (Raaiaum Hospital, Oslo, Norway). mAbs were used in a purified form or as hybridoma supernatants.

Peptides

Peptides were synthesized using Fmoc strategy and purified by preparative HPLC. They were characterized further by analytical HPLC and mass spectroscopy. The L1-RGD peptide was CWRGDGRDLQERGDSDK. For control the peptide VAIFYDM ESLPTGTW was used. The cyclic peptide GA*CRRETAWAC*GA has been reported to inhibit specifically human a5b1-mediated cell binding to fibronectin (47). The RGDs peptide was obtained from Sigma (Taufkirchen, Germany). Peptide-carrier protein conjugates for cell adhesion were produced by crosslinking N-succinimidy1 3-(2-pyridyldithio)propionate (SPDP) activated rabbit IgG with peptides via the NH2-terminal Cystein residue (4). Unconjugated IgG was used for control purposes in the binding assays. Peptide-carrier conjugates were coated to glass slides as described below. The cyclic RGD peptide 66203 (cycloRGDfV) that inhibits preferentially aV (Brooks et al., 1994) and 69601 (cycloRGDfV) (control peptide) were obtained from Dr. A. Jonczyk (E. Merck, Darmstadt, Germany).

Cytofluorography

The staining of cells with saturating amounts of mAbs, either hybridoma supernatants or purified antibodies, and phycoerythrin (PE)-conjugated goat antibodies to rat immunoglobulins (SERVA, Heidelberg, Germany), has been described elsewhere (50). Stained cells were analyzed with a FACS-Scan fluorescence activated cell analyzer (Becton Dickinson, Darmstadt, Germany).

Antibodies

mAbs 79 and M1.69 against mouse CD24 have been described before (42); mAbs 30G12 against mouse CD45; MK2.7 against VCAM-1, YN1/1.7 against ICAM-1, 324 and 555 against the L1 adhesion molecule, 12-15 against mouse CD24, mAb PS2, and 5/3 against a4 integrins were also described before (4, 51). mAbs FD41.8 (TIB 213) and FD 18.5 recognizing the a-chain of LFA-1 and ML70.15.1.5 (TIB 128) against the a-chain of Mac-1 were obtained from American Type Culture Collection (Rockville, MD) and were described before (2, 51). mAb 5H10-27 (MFRS) against CD49e (mouse a5) (mAb a5(1)) was obtained from Pharmingen (Dianova, Hamburg, Germany). HMa5-1 and HMa5-2 (mAb c5(2)) are blocking hamster mAbs against mouse a5 integrin (88). mAb RMV-7 is a blocking antibody to mouse vitronectin receptor on lymphocytes (79). mAb RB40.34 recognizing mouse P-selectin (12) was a gift of D. Vestweber (Max-Planck Institute für Immunobiologie, Freiburg, Germany). mAb EA-1 (39) against mouse a6 integrin was a gift of B. Imhof (BASF Institute for Immunology, Basel, Switzerland). The mAb to human VLA-5 (Sam-1) was obtained from Dianova. The anti-human CD24 mAb MLS was obtained from Dr. S. Funderud (Raaiaum Hospital, Oslo, Norway). mAbs were used in a purified form or as hybridoma supernatants.

Affinity Purification of Cell Surface Antigens

L1 was purified by affinity chromatography on a mAb 324 column from lysates of ESb-MP cells or N2A neuroblastoma cells essentially as described elsewhere (35). CD2 was isolated from mouse thymocyte lysate on a mAb 12-15-Sepharose column. The elution buffer contained 100 mM diethylamine/HC1, pH 11.5, 150 mM NaCl with 50 mM beta-octylglucoside (BOG). Soluble L1 from mouse brain was a gift from Dr. G. Kadmon (DKFZ, Heidelberg, Germany). VLA-5 was isolated from thymocyte lysate on a HMos-1-Sepharose column. The antigen was eluted with 0.2 M acetic acid, 50 mM BOG, 500 mM NaCl containing 2 mM CaCl2 and MgCl2. Eluted fractions were neutralized and analyzed by ELISA with respective antibodies and by SDS-PAGE. Purified antigens were stored at -20°C. For coating to polystyrene beads L1 antigen (~150 µg/ml) in BOG was incubated with the beads (SERVA) and the detergent was removed by dialysis as described (35). Remaining binding sites were blocked by incubation with 1% BSA in PBS for 1 h. The density of coated L1 was determined by FACS analysis using biotinylated mAb 324 followed by Streptavidin-Phycoerythrin (Dianova). The soluble mouse CD2

The Journal of Cell Biology, Volume 131, 1995 1882
CK fusion protein (the extracellular domains of CD2 fused to the constant part of the mouse γ light chain) was a kind gift of R. Rutschmann (Basel Institute for Immunology, Basel, Switzerland).

**Homotypic Cell Aggregation Assay**

For homotypic aggregation ESb-MP cells at 2 × 10⁶/ml were incubated in the presence of 10-50 μg/ml of purified mAb 79 to mouse CD24 in complete RPMI 1640 medium for 30 min at room temperature in 1.5-ml Eppendorf tubes. Tubes were rotated headwise to keep cells in suspension. At the end of incubation time the cells in medium were transferred to 24-well tissue culture plates, were allowed to sediment for 5 min and were then scored for aggregation.

**Heterotypic Cell Binding Assay**

For binding assays the bend3 endothelioma cells were grown to confluency in LABTEK glass chamber slides (Nunc, Wiesbaden, Germany). For platelet binding experiments the platelets were stimulated with PMA (10 ng/ml) for 10 min at room temperature, fixed with 2% formaldehyde, and adsorbed to LABTEK-slides for overnight at 4°C (2). Before the binding assay the slides were incubated in tissue culture medium containing 10% FBS to block residual binding sites. Cells or coated polysterene beads (2 × 10⁶/ml or 4 × 10⁶/ml, respectively) in HBSS containing 10 mM Hepes, 2 mM Ca²⁺ and Mg²⁺ (binding buffer) were incubated for 20 min at room temperature on the cell monolayer under constant shaking on a rotary platform (70-80 rpm). Slides were then dipped in PBS to remove unbound beads or cells, fixed with 2% glutaraldehyde and counted.

For binding of cells to purified L1 the antigen in BOG was diluted 1:10 to 1:30 with 10 mM Tris-HCl, pH 8.0, 150 mM NaCl (TBS), and were then coated to LABTEK slides for 16 h at 4°C. Wells were blocked with 1% BSA in PBS or 1% ovalbumin in TBS for 2 h at room temperature, washed with binding buffer and used for the assay. For binding, cells (5–10 × 10⁶/ml) were suspended in the same buffer and 0.2-ml aliquots were added to the coated slides. The binding assay was performed for 30 min at room temperature without shaking and the slides were washed and fixed as described above. For antibody or peptide-blocking studies, cells were preincubated with purified antibody or peptides at the indicated concentration for 10 min at room temperature and then transferred to the chamber slides. For Mn²⁺-activation, the Ca²⁺ and Mg²⁺ ions in the buffer were substituted with 0.5 mM Mn²⁺. Cell binding was measured by counting six independent 10× fields by video microscopy using IMAGE 1.47 software.

**Biochemical Analysis**

SDS-PAGE and Western blotting procedures have been described previously (40, 42, 54). Biotinylation of soluble L1 or the CD2-CK fusion protein was performed at ~100 μg/ml using a similar procedure as previously described for mAbs (35). Procedures for ELISA were also described before (41). For the binding of biotinylated antigens to VLA-5 the affinity-

---

**Figure 1.** CD24 induced homotypic aggregation of ESb-MP cells. (A) ESb-MP cells (2 × 10⁶/ml) were incubated under constant head-over-head rotation for 30 min in the presence of increasing concentrations of the inducing CD24 mAb (mAb 79) at room temperature. The cells were then transferred to a microtiter plate and photographed. (B) ESb-MP were activated for 30 min by mAb 79 (50 μg/ml) in the presence or absence of the indicated mAbs to L1 (324 and 555), VLA-5 (HMα5-1), L1-RGD peptide or a mAb to CD2 for control. (C) ESb-MP subclones with different L1 phenotype (L1hi or L1lo) were activated as described above. The phenotype of each subclone as assessed by FACS analysis is indicated. Bar, 83 μm.
isolated VLA-5 antigen (∼5 μg/ml) in BOG was coated to ELISA plates by dilution (1:10) with 10 mM Tris-HCl, pH 8.0, 150 mM NaCl containing 1 mM of each Ca²⁺, Mg²⁺, and Mn²⁺ ions (TBS plus ions). Affinity-purified L1 or CD2 were coated under similar conditions. All following washes and incubation steps with biotinylated L1 or CD2-Cx fusion protein (1 μg/ml) were carried out in the same buffer. Bound biotinylated antigens were detected by streptavidin-conjugated peroxidase (Dianova) and 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma) as substrate.

Statistical Analysis

Tests for statistical significance between the quantitative effects of different treatments were done using the Wilcoxon's rank sum test. Statements regarding differences are significant with a value of p < 0.0043.

Results

L1-mediated Homotypic Aggregation of ESb-MP Cells

We have shown in earlier studies that ESb-MP cells form homotypic cell aggregates that can be blocked by L1-specific antibodies (40, 50). This spontaneous aggregation occurred within 3 h at 37°C and was not seen in L10-expressing subclones of ESb-MP cells that were obtained from the parental subline suggesting an important role for L1 in this process (50). We now show that strong homotypic aggregation in shorter time can be induced in the presence of mAbs against mouse CD24. Fig. 1 A indicates that the CD24-specific mAb 79 caused aggregation within 30 min at 24°C in a dose-dependent manner. This effect was not dependent on the Fc-portion of the mAb since an isotype-matched control mAb (30G12) did not induce aggregation. Another mAb against CD24, i.e., M1.69, also caused aggregate formation (data not shown).

To examine whether the CD24-induced aggregation also involved L1, blocking studies were performed. As summarized in Table I and depicted in Fig. 1 B, a mixture of L1-specific mAbs (324 and 555) inhibited the aggregation, whereas control mAbs against CD2 (12-15), CD45 (30G12), ICAM-1 (YN 1/1.7), VCAM-1 (MK2.7) showed no effect. Soluble L1 at 2 μg/ml significantly reduced aggregate formation. Fig. 1 C indicates, that the L1β-expressing subclones 5 and 12 in contrast to the L1α subclone 8 could not undergo CD24-induced homotypic aggregation although the levels of CD24 and VLA-5 (see below) were comparable as judged by FACS analysis (not shown). These results suggested, that CD24 mAbs can drastically enhance the L1-mediated homotypic aggregation of ESb-MP cells.

ESb-MP Cell Aggregation Is Blocked by mAbs to VLA-5

L1 has been shown to participate in homophilic and heterophilic interactions (40, 53, 62). Since the homotypic aggregation of ESb-MP cells did not occur at 4°C (data not shown) we wondered whether the putative counter-receptor for L1 might be an integrin. We therefore analyzed ESb-MP cells for integrin expression. As shown in Fig. 2 A, ESb-MP cells expressed LFA-1, Mac-1, α4, α5, α6-integrins, and the vitronectin receptor αVβ3 as revealed by FACS staining with the respective mAbs. When these mAbs were tested for blocking capacity in the homotypic aggregation assay, only the two mAbs to VLA-5 showed significant inhibition (Table I and Fig. 1 B). All other mAbs to integrins or their respective cellular ligands as listed in Table I had no effect.

An L1-derived RGD-containing Peptide Inhibits Homotypic Aggregation

VLA-5 (α5β1) is a fibronectin receptor and binds to an RGD site in fibronectin. We reasoned that if VLA-5 would be a counter-receptor for L1 it might bind to the two RGD sites known to be present in close proximity in the Ig-domain VI of the L1 molecule (64). We therefore examined the effects of RGD-containing peptides on the CD24 induced aggregation of ESb-MP cells. As shown in Table I the peptide RGDS at 2 mg/ml effected the homotypic aggregation only weakly. In contrast, the RGD peptide CWRGDRDLQERGSDK derived from the 6th domain of L1 showed a good blocking effect that was dose dependent. At a concentration of 5 mg/ml peptide there was virtually no aggregation observed even after longer incubation times at 37°C although the cells remained viable as judged by tryphan blue exclusion. A control peptide VA1YDDESPLTGT in the same range of concentrations (1–5 mg/ml) had no effect on the aggregation. The cyclic peptide GA*CRR ETA WAC*GA which has been reported to inhibit specifically human α5β1-mediated cell binding to fibronectin (47) also showed an inhibitory ef-
Aggregation of ESb-MP Cells by mAbs and Peptides

Heterotypic Binding of Bone Marrow Cells to Platelets

Antibodies

<table>
<thead>
<tr>
<th>Antibodies</th>
<th>Antigen</th>
<th>Homotypic aggregation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medium</td>
<td>-</td>
<td>++ + + +</td>
</tr>
<tr>
<td>mAb 30G12</td>
<td>CD45</td>
<td>++ + + +</td>
</tr>
<tr>
<td>mAb 12-15</td>
<td>CD2</td>
<td>++ + + +</td>
</tr>
<tr>
<td>mAbs 324+555</td>
<td>L1</td>
<td>+</td>
</tr>
<tr>
<td>mAb MFR5</td>
<td>a5</td>
<td>+</td>
</tr>
<tr>
<td>mAb MHa5-2</td>
<td>a5</td>
<td>+</td>
</tr>
<tr>
<td>mAb EA-1</td>
<td>a6</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb RMV-7</td>
<td>aV</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb FD18-5</td>
<td>LFA-1</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb TIB123</td>
<td>LFA-1</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb TIB128</td>
<td>Mac-1</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb 5f3</td>
<td>a4</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb PS2</td>
<td>a4</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb VN 1/1.7</td>
<td>ICAM-1</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb MIC2/4</td>
<td>ICAM-2</td>
<td>+ + + + +</td>
</tr>
<tr>
<td>mAb MK2/7</td>
<td>VCAM-1</td>
<td>+ + + + +</td>
</tr>
</tbody>
</table>

Peptides

<table>
<thead>
<tr>
<th>Peptide</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>RGDS 2 mg/ml</td>
<td>+ + + +</td>
<td></td>
</tr>
<tr>
<td>L1-RGD 1 mg/ml</td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>L1-RGD 2 mg/ml</td>
<td>+ + +</td>
<td></td>
</tr>
<tr>
<td>L1-RGD 3 mg/ml</td>
<td>+ + + +</td>
<td></td>
</tr>
<tr>
<td>control peptide 2 mg/ml</td>
<td>+ + + +</td>
<td></td>
</tr>
<tr>
<td>GA<em>RETAACGA</em>GA 1 mg/ml</td>
<td>+ + + +</td>
<td></td>
</tr>
<tr>
<td>cyclo(RGDFV69601) 2 mg/ml</td>
<td>+ + + +</td>
<td></td>
</tr>
<tr>
<td>cyclo(RADIV69601) 2 mg/ml</td>
<td>+ + + +</td>
<td></td>
</tr>
</tbody>
</table>

Cells at 2 x 10^6/ml were incubated in the presence of 50 µg/ml mAb 79. Blocking antibodies were used at the concentration of 10 µg/ml. Peptides were used at the indicated concentrations. Note that all mAbs shown in this table can bind to ESb-MP cells as revealed by fluorescent staining except for the mAb to VCAM-1 for which the cells are negative. Data are compiled from >10 experiments in which each antibody was tested at least twice for inhibition. Aggregation scores are: - all cells free; + 10–20% cells aggregated; ++ 20–50% cells aggregated; +++ 50–75% cells aggregated; ++++ nearly all cells in aggregates.

Effect in the aggregation assay (see Table 1). In contrast, a cyclic RGD peptide that was shown to be specific for αv-integrins (15) and a cyclic control peptide had no effect.

**Heterotypic Binding of Bone Marrow Cells to Platelets Involves VLA-5**

The homotypic aggregation studies suggested a possible interaction of VLA-5 with L1 on adjacent cells as a novel mechanism of cell–cell binding. We examined whether this mechanism might also be effective in heterotypic cell adhesion. First we studied the binding of bone marrow cells (expressing L1; reference 50) to platelets that expressed VLA-5 (see Fig. 2 B) but no L1 (data not shown) and that had been immobilized to glass slides. Fig. 3 shows that the bone marrow cells could bind to the platelet monolayer and this binding was completely blocked by a mAb to P-selectin in agreement with previous results (2). Collectively, the data from both types of binding experiment suggested that in the heterotypic binding of bone marrow cells or ESb-MP cells to platelets the VLA-5/L1 binding pathway was active in addition to the P-selectin–ligand interaction.

**L1-Beads Bind to Platelets via VLA-5**

We next investigated whether affinity-isolated L1 could mediate binding to platelets via VLA-5. L1 was purified by affinity chromatography from ESb-MP or N2A neuroblastoma cell lysate, respectively. As shown in Fig. 4 A, the purified antigen showed the expected bands of 200 and 150 kD characteristic for L1 and its subfragment. The L1 antigen was adsorbed to polystyrene beads and as shown in Fig. 4 B could be detected by FACS analysis using L1-specific mAbs. We examined the binding of the L1-coated beads to platelets expressing VLA-5. Fig. 5 A shows that the L1 beads bound well to the immobilized platelets whereas control beads that had been coated with BSA did not bind. The binding was completely blocked by mAbs to L1 and to a lesser extent by mAbs to VLA-5. Control antibodies to CD2 or LFA-1 did not have an effect. The binding of L1 beads to platelets was significantly reduced in the presence of soluble L1 antigen. It was also blocked in the presence of the L1-RGD peptide in a dose-dependent manner whereas a control peptide had no effect.

**Binding of L1-Beads to Bend3 Endothelioma Cells**

The murine bend3 endothelioma cells expressed VLA-5 as revealed by FACS analysis (see Fig. 2 B). Since we observed previously that L1 beads could bind to bend3 endothelioma cells (35) we investigated a possible involvement of the VLA-5/L1 binding pathway in this interaction. As expected, the L1-coated beads could bind to bend3 endothelioma cells in a specific fashion and this binding was inhibited by mAbs to L1 but not by control mAbs (Fig. 5 B). In contrast to the platelet binding experiment, both mAbs to VLA-5 and the L1-RGD peptide were unable to block the binding. An inhibitory effect of the VLA-5 mAbs was also not seen after activation of endothelial cells with LPS for 4 h or when the binding assay was performed in the presence of Mn^2+ ions to activate the VLA-5 integrins (data not shown).
To analyze whether VLA-5 was expressed on the luminal surface of the cells fluorescent staining of the bend3 monolayer with specific mAbs was performed. Significant staining could be detected (data not shown) ruling out the possibility that VLA-5 was not accessible for the binding. Thus, we concluded that VLA-5 on the luminal site was functionally not active in bend3 cells. Importantly, the experiments indicated that bend3 endothelioma cells expressed another ligand for L1 distinct from VLA-5.

**Purified L1 and the L1-RGD Peptide Support Cell Binding**

We next studied whether purified L1 antigen or the L1-RGD peptide could mediate the adhesion of cells. The purified L1 was coated to glass slides and residual binding sites were blocked before the assay. We analyzed the binding ability of thymocytes that expressed VLA-5 (see Fig. 2 B). As shown in Fig. 6 A, thymocytes showed weak binding to the immobilized L1 that was however enhanced when the cells were activated in the presence of 0.5 mM...
Mn$^{2+}$ ions. The ESb-MP cells also showed weak binding to immobilized L1 that was enhanced by Mn$^{2+}$ treatment of the cells (data not shown). However, due to the ability of these cells to adhere to glass the background binding was much higher than with thymocytes.

To demonstrate direct binding of cells to the L1-RGD site the peptide CWRGDGRDLQERGDSK was conjugated to rabbit IgG as carrier and coated to glass slides in increasing concentrations. As shown in Fig. 6 B the L1-RGD peptide was very potent in promoting thymocyte adhesion which was again strongly enhanced by Mn$^{2+}$ activation. Normal IgG (nonconjugated) alone could not support cell adhesion. When the assay was carried out in the presence of Mn$^{2+}$ ions the binding of thymocytes to the L1-RGD-IgG was inhibited by both mAbs to VLA-5 as well as by the mixture of L1 mAbs but not by control mAbs, respectively (Fig. 6 C). Additional ELISA data indicated that the mixture of L1 mAbs were indeed able to bind to the immobilized L1-RGD-IgG but not to the control IgG (data not shown).

We also investigated whether L1 or the immobilized L1-RGD peptide could promote the binding of human Nalm-6 cells that are known to express VLA-5 (63). Nalm-6 cells could bind both to the L1 glycoprotein as well as to the L1-RGD peptide after Mn$^{2+}$ activation. The binding was blocked by mAb Sam-1 against human VLA-5 but not by a control mAb to human CD24 (Fig. 7). This suggested, that L1 could promote cell binding even across species barriers.

Figure 6. Binding of thymocytes to purified L1 or the L1-RGD peptide. Affinity-purified L1 antigen in BOG or the L1-RGD peptide coupled to carrier IgG (1 mg/ml) were coated to LABTEK chamber glass slides. Thymocytes in HBSS/10 mM Hepes containing 2 mM of each Ca$^{2+}$ and Mg$^{2+}$ (stripped bars) or, alternatively, in the presence of 0.5 mM Mn$^{2+}$ (solid bars) were tested for binding. Data are expressed as mean values ± SE. Three independent experiments with similar results were done. Area = 0.4 mm$^2$.

Figure 7. Binding of human Nalm-6 cells to purified L1 and the L1-RGD peptide. The L1 antigen in BOG and the L1-RGD peptide coupled to carrier IgG (1 mg/ml) were coated to LABTEK chamber glass slides. Purified CD24 (HSA) or normal unconjugated IgG served as control antigens. Human Nalm-6 pre-Bcells in HBSS/10 mM Hepes containing 0.5 mM Mn$^{2+}$ were tested for binding in the presence or absence of the indicated antibodies. Data are expressed as mean values ± SE. Two independent experiments with similar results were done. Area = 0.4 mm$^2$.
Demonstration of a Direct VLA-5–L1 Interaction

To demonstrate a direct interaction of VLA-5 and L1 an ELISA-based assay was employed. Soluble L1 was biotinylated and allowed to bind to immobilized VLA-5 or L1 antigen. The heterophilic binding to VLA-5 was dependent on divalent cations since it was not seen in the presence of EDTA/EGTA. In contrast, the homophilic L1–L1 binding was rather insensitive to EDTA/EGTA treatment in agreement with the notion that the L1–L1 binding is Ca2+ and Mg2+ independent. In the presence of the L1-RGD peptide (at 500 μg/ml) the binding of L1 to VLA-5 was inhibited by ~80%. Biotinylated L1 did not bind to immobilized CD2. Conversely, a biotinylated CD2–Cκ fusion protein was unable to bind VLA-5 (data not shown). These results confirmed the functional data on a level of protein–protein interaction.

Discussion

The analysis of homotypic cell aggregation, either spontaneous or induced, has been helpful for the elucidation of general adhesion mechanisms. For the integrin-mediated homotypic aggregation of lymphocytes the interaction of LFA-1 with ICAMs and the α4-integrin–mediated binding pathway have been identified (18). A counter ligand for α4-integrins on lymphocytes has not been found, and there is suggestive evidence that a homophilic α4–α4 integrin binding may be involved (4, 68). In the present report we analyzed the homotypic aggregation induced in ESb-MP cells by treatment with mAbs to the glycosylphosphatidylinositol (GPI)-anchored molecule CD24. These cells can undergo spontaneous aggregation that occurs slowly, requires low divalent cation concentrations and is completely blocked by polyclonal antibodies to L1 (40, 50). In the presence of mAbs to CD24 the aggregation was drastically increased and was detectable in much shorter time. The available data suggested a novel mechanism of homotypic cell binding by VLA-5 integrin and L1 via RGD epitope(s) which were also involved in the heterotypic binding of bone marrow cells or ESb-MP cells to immobilized platelets.

Additional proof for a VLA-5–L1 binding came from studies in which the purified L1 antigen was coated to polystyrene beads or immobilized to glass slides. In the latter case a VLA-5–mediated binding to L1 as well as to the L1-derived RGD peptide was seen with mouse thymocytes and human Nalm-6 cells. In thymocytes the level of binding to these substrates was poor however was drastically enhanced after Mn2+ treatment of the cells. The L1 antigen-coated polystyrene beads were able to bind to platelets and bend3 endothelioma cells expressing VLA-5. The binding to both substrates was dependent on L1 and could be blocked by mAbs to L1. Binding to platelets was also inhibited by mAbs to VLA-5 and by the L1-RGD peptide whereas the binding to the endothelioma cells was clearly not affected. This was surprising since VLA-5 was detectable at the luminal cell surface of endothelioma cells and was therefore accessible for the binding of the beads. It is likely that in polarized cells like endothelial cells VLA-5 may be in different affinity states dependent on the localization of the integrin (22). Cultured human endothelial cells express integrins including VLA-5 on the luminal and basolateral site however assemble fibronectin matrix at their basolateral surface (52). Also differentiated monocytic cells express two populations of fibronectin receptors: a minority in a high affinity state and the majority in a low affinity state (25). This could explain why in endothelioma cells the VLA-5 was unable to bind to L1. However, the L1-dependent binding of the beads observed suggested an additional ligand distinct from VLA-5 in these cells which has not yet been identified.

Previously we characterized CD24 as a ligand for P-selectin on ESb-MP cells, granulocytes, and monocytes (2, 73). MAbs to CD24 could block P-selectin–mediated binding of myeloid cells to platelets or endothelioma cells in the cold (2). In this report we show that at room temperature or above CD24-specific mAbs could specifically enhance homotypic aggregation of ESb-MP cells by a VLA-5–L1 pathway. The mechanism of this effect is presently unknown. It is likely that the slow spontaneous aggregation of ESb-MP cells is due to the previously described homotypic L1–L1 interaction (42, 50). The role of CD24 mAbs could be to activate an additional VLA-5–L1 heterotypic binding pathway leading to the observed enhanced cell clustering. Such activation of cell adhesiveness could happen by either stimulating the α5-integrin via signaling or by the induction of conformational changes in the VLA-5 integrin. Similar activation of fibronectin receptors including VLA-5 has been reported after treatment of cells with stem cell factor (49), mAbs to ICAM-3 (19) or CD9 (60). A second possibility is...
that the binding of CD24 mAbs may lead to a conformational change of the L1 adhesion molecule. Indeed, studies by Kadmon et al. (44) have implicated a cis-interaction and functional cooperation of CD24 and L1 in neurones but not in B lymphoblasts. Interestingly, recent structural studies of integrin-ligand interaction have indicated that amino acids adjacent to the integrin-binding sequence may be critical for ligand recognition (for review see reference 32). A given RGD site could be cryptic and only exposed after conformational changes. This concept of ligand activation emphasizes the importance of local secondary structure and protein folding in regulating the functional state of integrin ligands. We can not exclude at present whether such a model may be applicable to at least some forms of L1 or not.

Evidence for a role of CD24 in the regulation of the cell adhesion comes also from other systems. In B lymphoblasts different mAbs to CD24 could either activate LFA-1-dependent cell aggregation (43) or could inhibit cell aggregation (42). In a study on pre-B cell lines in which either CD24 was inactivated by gene targeting or expression restored by transfection it was shown that CD24 influenced the avidity of α4-integrins (31, 45). In cells of the myeloid lineage CD24 appears to have two roles: a ligand for P-selectin and a signaling molecule for the activation of the VLA-5 integrin.

It is at present difficult to assess in which cellular interactions a VLA-5-L1 binding could be involved. The role of VLA-5 has been studied in aspects of myeloid cell differentiation (8, 25), interaction with bone marrow stromal cells (72), the growth and differentiation of hematopoietic cells (6, 23, 78, 82), embryogenesis (87) and cell migration (7, 63) mainly focussing on the ability of this receptor to bind to fibronectin. Some reports have also described a potential function for VLA-5 in cell-cell interactions (5, 57).

It is at present difficult to assess in which cellular interactions a VLA-5-L1 binding could be involved. The role of VLA-5 has been studied in aspects of myeloid cell differentiation (8, 25), interaction with bone marrow stromal cells (72), the growth and differentiation of hematopoietic cells (6, 23, 78, 82), embryogenesis (87) and cell migration (7, 63) mainly focussing on the ability of this receptor to bind to fibronectin. Some reports have also described a potential function for VLA-5 in cell-cell interactions (5, 57).

Since the L1 adhesion molecule is expressed by a wide variety of cells including neural cells, intestinal epithelium (81) and leukocytes (50), putative interactions with VLA-5 being also expressed on many cells would be possible. At present we can not exclude that other integrins which are known to recognize the RGD sequence in a variety of extracellular matrix proteins may also be able to interact with the L1 adhesion molecule. It should also be noted that in contrast to the mouse the human L1 homologue has only one RGD site in the VI. Ig domain. At present we therefore can not extrapolate from our findings to the role of L1 in other species.

In the nervous system L1 is involved in granule neuron migration in the developing mouse cerebellar cortex (58), the fasciculation of neurites (27) and neurite outgrowth on other neurites and Schwann cells (21, 74). Neurite outgrowth in vitro can be stimulated by purified L1 (55), by transfected L1 expressed on monolayers of 3T3 fibroblasts (83) or with an L1-Fe-chimeric in solution (24). Preincubation of neurones with antibodies to L1 could inhibit the stimulated outgrowth of neurites implicating a predominantly homotypic L1-L1 interaction (24). Neurite outgrowth is influenced by the substrate and occurs also on extracellular matrix components (1, 11, 85) as well as on for example tissue sections of embryonic muscle where it is largely integrin-dependent (33). Expression of fibronectin receptors has been demonstrated in the mouse nervous system including some neurons (66). Although VLA-5 on the nerve growth cone has not formally been demonstrated, its expression is not unlikely since VLA-5 can participate in the endocytotic cycle and can be brought to the leading edge of a moving cell (14). It is therefore possible that neurite outgrowth on L1 substrate involves VLA-5 integrin. A role of β1-integrins (which includes VLA-5) in the neurite outgrowth on CAMs was indeed suggested in studies on TAG-1. TAG-1 is structurally related to L1 and comprises six Ig domains and four fibronectin type III repeats with an RGD site located in the second repeat (28). Although TAG-1 can mediate homophilic binding, the neurite outgrowth on TAG-1 required an L1-like molecule and β1-integrins on the neurites (26). Antibodies to β1-integrins could block the neurite extension on TAG-1 substrate but not on NgCAM, a putative chick homologue to L1. These data do not support the assumption of an important role for the VLA-5/L1 pathway in neurite growth. However, structurally NgCAM and L1 show significant differences in overall sequence and are also different in the localisation of RGD sequences (16). VLA-5 could be involved in cases where the growth of neurones is studied on other cells i.e. fibroblasts or neural cells. Fibroblasts do express VLA-5 and in earlier studies fibronectin receptors (likely to include VLA-5) were also shown to be expressed by neural cells (66).

The signaling via CAMs like L1, N-CAM, or N-cadherin that ultimately leads to the growth of neuronal processes has been recently linked to the FGF-receptors (84). The VLA-5 integrin has also been implicated, at least in part, to play a role in growth regulation (70). For tumor cells it has been shown that cells selected for low expression of α5β1 are more tumorigenic than higher expressors (77) and that transfection of α5β1 into CHO cells suppresses the growth, migration and tumorigenicity of these cells (29).

The mechanism of this growth regulation is not entirely clear however may be related to the ligand occupancy of the VLA-5 integrin (70, 71). In a previous study we investigated the tumorigenicity of L1hi and L1lo subclones of ESb-MP in syngeneic mice (51). We found that animals bearing L1lo subclone tumors died significantly earlier than L1hi animals. The earlier death was due to a much faster growth of the primary tumor and an earlier onset of metastasis. The finding presented in this paper that L1 and VLA-5 are receptor and ligand on these cells that are used for homotypic cell interaction could be relevant to explain the tumor growth results. In this context it is interesting to note, that in resting lymphocytes after the induction of proliferation in vivo or in vitro the L1 molecule is rapidly downregulated (35). This suggests that the VLA-5-L1 interaction may be more important in non-proliferating cells.

In summary, we have shown that L1 adhesion molecule is a ligand to VLA-5 integrin and that this newly established interaction may be important in diverse cell-cell interactions.

We thank C. Geiger for excellent technical assistance and S. Marei and V. Schirrmacher for support and stimulating discussions. We are grateful to R. Pipkorn for peptide synthesis, M. Schachner, G. Kadmon, and A. Feissner for gifts of antibodies and purified L1.

This work was supported by a grant from Deutsche Forschungsgemeinschaft to F. Altevogt (AI 170/4-1).

Received for publication 30 May 1995 and in revised form 4 August 1995.
References


